Perspective on Tumor Organoids in Drug Screening and Cancer Precision Medicine
Journal of Organoid and Bioscience · 2024
DOI: 10.62714/zlsh6629 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Organoid and Bioscience, 2024. Verfasst von Lingzhi Wang.
Abstract (Originalsprache)
The landscape of cancer research is swiftly evolving, presenting fresh optimism through innovative tactics that customize treatment for each patient. In 2016, Clevers unveiled a groundbreaking study in Cell, introducing organoids that emulate essential structural and functional traits of organs like the kidney, lung, gut, brain, and retina. This technology enables the replication of human organ development and various pathologies within a controlled laboratory environment. Mounting evidence underscores the potential of patient-derived organoids (PDOs) to reshape cancer treatment and revolutionize drug discovery in oncology. This commentary explores these pioneering research avenues and their profound implications for clinical oncology and pharmaceutical development.
Zitieren
APA
Wang, L. (2024). Perspective on Tumor Organoids in Drug Screening and Cancer Precision Medicine. Journal of Organoid and Bioscience. https://doi.org/10.62714/zlsh6629
Vancouver
Wang L. Perspective on Tumor Organoids in Drug Screening and Cancer Precision Medicine. Journal of Organoid and Bioscience. 2024. doi:10.62714/zlsh6629
BibTeX
@article{Wang2024,
author = {Wang, Lingzhi},
title = {Perspective on Tumor Organoids in Drug Screening and Cancer Precision Medicine},
journal = {Journal of Organoid and Bioscience},
year = {2024},
doi = {10.62714/zlsh6629}
}
EUVIMED